Immodulon is an independent biopharmaceutical company pioneering immunotherapy treatments, in particular for cancer.
Immunotherapy is now recognised as the biggest breakthrough since chemotherapy in the treatment of cancer. Immodulon’s research demonstrates that its lead product is improving the overall outcome for patients when used in combination with other anti-cancer treatments.
IMM‑101 is a naturally derived investigational medicinal product that helps the body’s immune system to recognise and control cancer. It is intended to be used in combination with other anti-cancer treatments to improve the overall outcome for patients. Clinical studies have produced encouraging increases in survival data in patients with pancreatic cancer and advanced melanoma.
Immodulon is an independent biopharmaceutical company that has attracted significant investment to date, exclusively from private investors.
Latest News & Research
News29 November 2017Immodulon Therapeutics Strengthens Board with New AppointmentsRead more
News19 May 2017Laura Rosa Brunet, Immodulon’s Chief Scientific Officer, published in Journal for ImmunoTherapy of CancerRead more
News02 May 2017Grant awarded to Professor Stefan Reber for work involving IMM-201Read more
Events10 March 2017Immodulon’s Chief Scientific Officer, Laura Rosa Brunet, speaks at Targeted Anticancer Therapies CongressRead more
Events04 February 2017Immodulon's Chief Scientific Officer speaks at Immuno-Oncology 360°Read more